688553 汇宇制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.7423.7336.84420.69059.185
总资产报酬率 ROA (%)1.3883.1195.92416.69233.128
投入资产回报率 ROIC (%)1.5283.4716.65719.86651.002

边际利润分析
销售毛利率 (%)82.28385.92988.20291.37591.479
营业利润率 (%)12.22013.41515.76726.25129.175
息税前利润/营业总收入 (%)12.5729.74612.82425.92229.295
净利润/营业总收入 (%)11.68815.02916.67424.44825.057

收益指标分析
经营活动净收益/利润总额(%)68.83840.37979.26392.37795.461
价值变动净收益/利润总额(%)12.03330.73918.9693.9783.310
营业外收支净额/利润总额(%)8.8325.8921.235-0.221-0.390

偿债能力分析
流动比率 (X)2.9273.2645.4586.5601.916
速动比率 (X)2.7603.0905.1436.1971.677
资产负债率 (%)21.10519.44713.05813.82838.034
带息债务/全部投入资本 (%)12.83610.2951.7080.7681.012
股东权益/带息债务 (%)674.016863.9905,704.06912,635.0919,013.538
股东权益/负债合计 (%)373.729413.795665.802623.195162.921
利息保障倍数 (X)-15.130-2.161-4.083-95.398125.526

营运能力分析
应收账款周转天数 (天)18.95619.1796.5942.4724.802
存货周转天数 (天)300.497440.314352.322312.971224.871